Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InSilico Medicine Cayman TopCoFRA:O15 +3.96%20 PS Ratio is 60.34 as of Aug. 27, 2026, which is 534% above its 10-year median of 9.52. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 2,791 Software companies, InSilico Medicine Cayman TopCo ranks worse than 97.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, InSilico Medicine Cayman TopCo's share price is €5.25.
InSilico Medicine Cayman TopCo's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.09. Hence, InSilico Medicine Cayman TopCo's PS Ratio for today is 60.34.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's PS Ratio or its related term are showing as below:
FRA:O15'
s PS Ratio Range Over the Past 10 Years
Min: 6.09 Med: 9.52 Max: 61.93
Current: 61.93
During the past 4 years, InSilico Medicine Cayman TopCo's highest PS Ratio was 61.93. The lowest was 6.09. And the median was 9.52.
FRA:O15's PS Ratio is ranked worse than 97.03% of 2791
companies
in the Software industry
Industry Median: 1.95
vs FRA:O15: 61.93
During the past 4 years, InSilico Medicine Cayman TopCo's highest 3-Year average Revenue per Share Growth Rate was 136.40% per year. The lowest was 136.40% per year. And the median was 136.40% per year.
InSilico Medicine Cayman TopCo (FRA:O15) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
InSilico Medicine Cayman TopCo PS Ratio Related Terms
InSilico Medicine Cayman TopCo PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo PS Ratio vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's PS Ratio distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's PS Ratio falls into.
InSilico Medicine Cayman TopCo PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
InSilico Medicine Cayman TopCo's Share Price of today is €5.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. InSilico Medicine Cayman TopCo's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.09.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
InSilico Medicine Cayman TopCo (FRA:O15) has a PS Ratio of 60.34 as of Aug. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on InSilico Medicine Cayman TopCo and its competitors. This is 534% above median its historical median of 9.52. Over the past decade, InSilico Medicine Cayman TopCo's PS Ratio has ranged from 6.09 to 61.93. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #2708 out of 2791 companies in the Software industry, placing it in the top 97%.
Is InSilico Medicine Cayman TopCo's PS Ratio too high?
InSilico Medicine Cayman TopCo's current PS Ratio of 60.34 is 534% above median its 10-year median of 9.52. Over the past 10 years, this metric has ranged from a low of 6.09 to a high of 61.93. The Software industry median PS Ratio is 1.95. InSilico Medicine Cayman TopCo's value of 60.34 is 2994.4% above this industry median. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #2708 out of 2791 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's PS Ratio compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #2708 out of 2791 companies for PS Ratio. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median PS Ratio is 1.95. InSilico Medicine Cayman TopCo's value of 60.34 is 2994.4% above this benchmark. Historically, InSilico Medicine Cayman TopCo's own PS Ratio has ranged from 6.09 to 61.93 over the past decade. While the company's 10-year median is 9.52 vs. the industry median of 1.95, InSilico Medicine Cayman TopCo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Software company?
The median PS Ratio among Software companies is 1.95, based on 2,791 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InSilico Medicine Cayman TopCo's current PS Ratio of 60.34 is 2994.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median PS Ratio is 1.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current PS Ratio is 60.34, which is 534% above median its own 10-year median of 9.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current PS Ratio of 60.34. The current PS Ratio is 60.34, which is 534% above median its 10-year median of 9.52 and 2994.4% above the Software industry median of 1.95. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current PS Ratio is 60.34 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
